Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex-Reference-Cited by-同舟云学术

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

Published:2014-12-10 Issue:7536 Volume:517 Page:583-588
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Konermann Silvana,Brigham Mark D.,Trevino Alexandro E.,Joung Julia,Abudayyeh Omar O.,Barcena Clea,Hsu Patrick D.,Habib Naomi,Gootenberg Jonathan S.,Nishimasu Hiroshi,Nureki Osamu,Zhang Feng

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature14136.pdf

Reference51 articles.

1. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431–437 (2004)

2. Boutros, M. et al. Genome-wide RNAi analysis of growth and viability in Drosophila cells. Science 303, 832–835 (2004)

3. Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014)

4. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80–84 (2014)

5. Beerli, R. R., Segal, D. J., Dreier, B. & Barbas, C. F., III Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl Acad. Sci. USA 95, 14628–14633 (1998)

Cited by 2331 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LINC00894 inhibited neuron cellular apoptosis and regulated activating transcription factor 3 expression;Gene;2024-11

2. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates the ZNF334 gene to inhibit the growth of colorectal cancer;International Journal of Biological Macromolecules;2024-10

3. Specific small interfering RNAs (siRNAs) for targeting the metastasis, immune responses, and drug resistance of colorectal cancer cells (CRC);International Immunopharmacology;2024-10

4. CRISPR editing of candidate host factors that impact influenza A virus infection;2024-09-11

5. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10